Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/14266
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mattick, R. | - |
dc.contributor.author | Ali, R. | - |
dc.contributor.author | White, J. | - |
dc.contributor.author | O'Brien, S. | - |
dc.contributor.author | Wolk, S. | - |
dc.contributor.author | Danz, C. | - |
dc.date.issued | 2003 | - |
dc.identifier.citation | Addiction, 2003; 98(4):441-452 | - |
dc.identifier.issn | 0965-2140 | - |
dc.identifier.issn | 1360-0443 | - |
dc.identifier.uri | http://hdl.handle.net/2440/14266 | - |
dc.description | The definitive version is available at www.blackwell-synergy.com | - |
dc.description.abstract | AIMS: To assess the efficacy of buprenorphine compared with methadone maintenance therapy for opioid dependence in a large sample using a flexible dosing regime and the marketed buprenorphine tablet. DESIGN: Patients were randomized to receive buprenorphine or methadone over a 13-week treatment period in a double-blind, double-dummy trial. SETTING: Three methadone clinics in Australia. PARTICIPANTS: Four hundred and five opioid-dependent patients seeking treatment. INTERVENTION: Patients received buprenorphine or methadone as indicated clinically using a flexible dosage regime. During weeks 1–6, patients were dosed daily. From weeks 7–13, buprenorphine patients received double their week 6 dose on alternate days. MEASUREMENT: Retention in treatment, and illicit opioid use as determined by urinalysis. Self-reported drug use, psychological functioning, HIV-risk behaviour, general health and subjective ratings were secondary outcomes. FINDINGS: Intention-to-treat analyses revealed nO significant difference in completion rates at 13 weeks. Methadone was superior to buprenorphine in time to termination over the 13-week period (Wald c 2 = 4.371, df = 1,P = 0.037), but not separately for the single-day or alternate-day dosing phases. There were no significant between-group differences in morphine-positive urines, or in self reported heroin or other illicit drug use. The majority (85%) of the buprenorphine patients transferred to alternate-day dosing were maintained in alternate-day dosing. CONCLUSIONS: Buprenorphine did not differ from methadone in its ability to suppress heroin use, but retained approximately 10% fewer patients. This poorer retention was due possibly to too-slow induction onto buprenorphine. For the majority of patients, buprenorphine can be administered on alternate days. | - |
dc.description.statementofresponsibility | Richard P. Mattick, Robert Ali, Jason M. White, Susannah O’Brien, Seija Wolk and Cath Danz | - |
dc.language.iso | en | - |
dc.publisher | Carfax Publishing | - |
dc.source.uri | http://www.blackwell-synergy.com/doi/abs/10.1046/j.1360-0443.2003.00335.x | - |
dc.subject | Buprenorphine | - |
dc.subject | methadone | - |
dc.subject | opioid dependence | - |
dc.subject | randomized trial | - |
dc.subject | treatment outcome. | - |
dc.title | Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1046/j.1360-0443.2003.00335.x | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Ali, R. [0000-0003-2905-8153] | - |
Appears in Collections: | Aurora harvest 2 Pharmacology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.